Complete response of a highly advanced gastric carcinoma to preoperative chemoradiotherapy with S-1 and low-dose cisplatin

Nobunari Yoshimizu, Yoshiro Saikawa, Tetsuro Kubota, Yasutada Akiba, Masashi Yoshida, Yoshihide Otani, Koichiro Kumai, Toshihumi Hibi, Masaki Kitajima

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

S-1 has been developed as a new oral anticancer drug, based on the biological modulation of 5-fluorouracil. We report a patient with highly advanced gastric carcinoma who was treated successfully with a new combination chemoradiotherapy using S-1 and cisplatin (CDDP). The patient was a 37-year-old man who was diagnosed with advanced gastric carcinoma (T4N3M0) that had invaded the diaphragm and the paraaortic tissues. Remarkable tumor reduction was observed in the primary tumor and metastatic lymph nodes around the stomach after three cycles of the therapy. Radiological examination before surgery determined that a partial response (PR) had been achieved by the initial therapy. Adverse effects included only a gastrointestinal disorder that was limited to grade 2 when low-dose CDDP was utilized in the regimen, while an initial high dose of CDDP resulted in grade 3 toxicity, due to myelosuppression. The patient underwent curative surgery, including total gastrectomy, D2 lymph node dissection, and splenectomy, after completion of the radiochemotherapy regimen. No surgical complication was observed. No tumor cells were detected by pathological evaluation of the resected stomach and all the regional lymph nodes, confirming a pathological complete response (CR; grade 3). This regimen is a potent treatment for advanced gastric carcinoma, especially when used as preoperative chemotherapy to control cancer cells.

Original languageEnglish
Pages (from-to)185-190
Number of pages6
JournalGastric Cancer
Volume6
Issue number3
DOIs
Publication statusPublished - 2003

Fingerprint

Chemoradiotherapy
Cisplatin
Stomach
Carcinoma
Neoplasms
Lymph Nodes
Splenectomy
Gastrectomy
Diaphragm
Lymph Node Excision
Fluorouracil
Therapeutics
Drug Therapy
Pharmaceutical Preparations

Keywords

  • Cisplatin
  • Complete response
  • Gastric cancer
  • Radiation
  • S-1

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology
  • Cancer Research

Cite this

Yoshimizu, N., Saikawa, Y., Kubota, T., Akiba, Y., Yoshida, M., Otani, Y., ... Kitajima, M. (2003). Complete response of a highly advanced gastric carcinoma to preoperative chemoradiotherapy with S-1 and low-dose cisplatin. Gastric Cancer, 6(3), 185-190. https://doi.org/10.1007/s10120-003-0239-2

Complete response of a highly advanced gastric carcinoma to preoperative chemoradiotherapy with S-1 and low-dose cisplatin. / Yoshimizu, Nobunari; Saikawa, Yoshiro; Kubota, Tetsuro; Akiba, Yasutada; Yoshida, Masashi; Otani, Yoshihide; Kumai, Koichiro; Hibi, Toshihumi; Kitajima, Masaki.

In: Gastric Cancer, Vol. 6, No. 3, 2003, p. 185-190.

Research output: Contribution to journalArticle

Yoshimizu, N, Saikawa, Y, Kubota, T, Akiba, Y, Yoshida, M, Otani, Y, Kumai, K, Hibi, T & Kitajima, M 2003, 'Complete response of a highly advanced gastric carcinoma to preoperative chemoradiotherapy with S-1 and low-dose cisplatin', Gastric Cancer, vol. 6, no. 3, pp. 185-190. https://doi.org/10.1007/s10120-003-0239-2
Yoshimizu, Nobunari ; Saikawa, Yoshiro ; Kubota, Tetsuro ; Akiba, Yasutada ; Yoshida, Masashi ; Otani, Yoshihide ; Kumai, Koichiro ; Hibi, Toshihumi ; Kitajima, Masaki. / Complete response of a highly advanced gastric carcinoma to preoperative chemoradiotherapy with S-1 and low-dose cisplatin. In: Gastric Cancer. 2003 ; Vol. 6, No. 3. pp. 185-190.
@article{827fec8b9c36482ea4b12252eb73ff60,
title = "Complete response of a highly advanced gastric carcinoma to preoperative chemoradiotherapy with S-1 and low-dose cisplatin",
abstract = "S-1 has been developed as a new oral anticancer drug, based on the biological modulation of 5-fluorouracil. We report a patient with highly advanced gastric carcinoma who was treated successfully with a new combination chemoradiotherapy using S-1 and cisplatin (CDDP). The patient was a 37-year-old man who was diagnosed with advanced gastric carcinoma (T4N3M0) that had invaded the diaphragm and the paraaortic tissues. Remarkable tumor reduction was observed in the primary tumor and metastatic lymph nodes around the stomach after three cycles of the therapy. Radiological examination before surgery determined that a partial response (PR) had been achieved by the initial therapy. Adverse effects included only a gastrointestinal disorder that was limited to grade 2 when low-dose CDDP was utilized in the regimen, while an initial high dose of CDDP resulted in grade 3 toxicity, due to myelosuppression. The patient underwent curative surgery, including total gastrectomy, D2 lymph node dissection, and splenectomy, after completion of the radiochemotherapy regimen. No surgical complication was observed. No tumor cells were detected by pathological evaluation of the resected stomach and all the regional lymph nodes, confirming a pathological complete response (CR; grade 3). This regimen is a potent treatment for advanced gastric carcinoma, especially when used as preoperative chemotherapy to control cancer cells.",
keywords = "Cisplatin, Complete response, Gastric cancer, Radiation, S-1",
author = "Nobunari Yoshimizu and Yoshiro Saikawa and Tetsuro Kubota and Yasutada Akiba and Masashi Yoshida and Yoshihide Otani and Koichiro Kumai and Toshihumi Hibi and Masaki Kitajima",
year = "2003",
doi = "10.1007/s10120-003-0239-2",
language = "English",
volume = "6",
pages = "185--190",
journal = "Gastric Cancer",
issn = "1436-3291",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - Complete response of a highly advanced gastric carcinoma to preoperative chemoradiotherapy with S-1 and low-dose cisplatin

AU - Yoshimizu, Nobunari

AU - Saikawa, Yoshiro

AU - Kubota, Tetsuro

AU - Akiba, Yasutada

AU - Yoshida, Masashi

AU - Otani, Yoshihide

AU - Kumai, Koichiro

AU - Hibi, Toshihumi

AU - Kitajima, Masaki

PY - 2003

Y1 - 2003

N2 - S-1 has been developed as a new oral anticancer drug, based on the biological modulation of 5-fluorouracil. We report a patient with highly advanced gastric carcinoma who was treated successfully with a new combination chemoradiotherapy using S-1 and cisplatin (CDDP). The patient was a 37-year-old man who was diagnosed with advanced gastric carcinoma (T4N3M0) that had invaded the diaphragm and the paraaortic tissues. Remarkable tumor reduction was observed in the primary tumor and metastatic lymph nodes around the stomach after three cycles of the therapy. Radiological examination before surgery determined that a partial response (PR) had been achieved by the initial therapy. Adverse effects included only a gastrointestinal disorder that was limited to grade 2 when low-dose CDDP was utilized in the regimen, while an initial high dose of CDDP resulted in grade 3 toxicity, due to myelosuppression. The patient underwent curative surgery, including total gastrectomy, D2 lymph node dissection, and splenectomy, after completion of the radiochemotherapy regimen. No surgical complication was observed. No tumor cells were detected by pathological evaluation of the resected stomach and all the regional lymph nodes, confirming a pathological complete response (CR; grade 3). This regimen is a potent treatment for advanced gastric carcinoma, especially when used as preoperative chemotherapy to control cancer cells.

AB - S-1 has been developed as a new oral anticancer drug, based on the biological modulation of 5-fluorouracil. We report a patient with highly advanced gastric carcinoma who was treated successfully with a new combination chemoradiotherapy using S-1 and cisplatin (CDDP). The patient was a 37-year-old man who was diagnosed with advanced gastric carcinoma (T4N3M0) that had invaded the diaphragm and the paraaortic tissues. Remarkable tumor reduction was observed in the primary tumor and metastatic lymph nodes around the stomach after three cycles of the therapy. Radiological examination before surgery determined that a partial response (PR) had been achieved by the initial therapy. Adverse effects included only a gastrointestinal disorder that was limited to grade 2 when low-dose CDDP was utilized in the regimen, while an initial high dose of CDDP resulted in grade 3 toxicity, due to myelosuppression. The patient underwent curative surgery, including total gastrectomy, D2 lymph node dissection, and splenectomy, after completion of the radiochemotherapy regimen. No surgical complication was observed. No tumor cells were detected by pathological evaluation of the resected stomach and all the regional lymph nodes, confirming a pathological complete response (CR; grade 3). This regimen is a potent treatment for advanced gastric carcinoma, especially when used as preoperative chemotherapy to control cancer cells.

KW - Cisplatin

KW - Complete response

KW - Gastric cancer

KW - Radiation

KW - S-1

UR - http://www.scopus.com/inward/record.url?scp=0141892587&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141892587&partnerID=8YFLogxK

U2 - 10.1007/s10120-003-0239-2

DO - 10.1007/s10120-003-0239-2

M3 - Article

C2 - 14520533

AN - SCOPUS:0141892587

VL - 6

SP - 185

EP - 190

JO - Gastric Cancer

JF - Gastric Cancer

SN - 1436-3291

IS - 3

ER -